Stanley T. Crooke net worth and biography

Stanley Crooke Biography and Net Worth

Chairman of Ionis Pharmaceuticals

Stanley Crooke is the founder and executive chairman of Ionis Pharmaceuticals, Inc.

Crooke founded Ionis (then known as Isis Pharmaceuticals) in 1989, and became a leader in RNA-targeted therapeutics. Under his guidance, the company developed cutting-edge antisense technology and established one of the most advanced pipelines in the biotechnology industry.

Today, more than 40 medicines are in development at Ionis. In December 2020, Crooke announced his retirement from the company and its board of directors effective June 2021.

At the start of his career, Crooke helped to establish the first broad anticancer program at Bristol-Myers, bringing nine drugs to market in five years. Before founding Ionis, he was the president of research and development at Smithkline & French Laboratories U.S. Inc., where he helped commercialize numerous drugs in various therapeutic areas. He went on to lead worldwide research and development efforts at Smithkline Beckman.

Crooke is credited with leading the development of over 20 marketed drugs throughout his career and supporting the establishment and growth of several companies using Ionis’ antisense technology.

He has been recognized with numerous awards and accolades, including the Massry Prize, the Oligonucleotide Therapeutics Society Lifetime Achievement Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Prix Galien Best Biotechnology Award, the Lifetime Achievement Award from Scrip, and the Helix Award from the Biotechnology Industry Organization, among others.

Crooke earned his undergraduate degree at Butler University and his graduate and doctorate degrees from the Baylor College of Medicine. He has also published more than 450 scientific publications.

Following his retirement, Crooke plans to focus on his scientific interests and his nonprofit organization, the n-Lorem Foundation. He will remain a scientific advisor to Ionis, including to the core antisense research group and in the areas of research and development programs.

What is Stanley T. Crooke's net worth?: The estimated net worth of Stanley T. Crooke is at least $60,023.70 as of January 26th, 2021. Mr. Crooke owns 2,021 shares of Ionis Pharmaceuticals stock worth more than $60,024 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Crooke may own. Learn More about Stanley T. Crooke's net worth.
How do I contact Stanley T. Crooke?: The corporate mailing address for Mr. Crooke and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at wwalke@ionisph.com. Learn More on Stanley T. Crooke's contact information.
Has Stanley T. Crooke been buying or selling shares of Ionis Pharmaceuticals?: Stanley T. Crooke has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, Stanley T. Crooke sold 28,333 shares of the business's stock in a transaction on Tuesday, January 26th. The shares were sold at an average price of $63.74, for a transaction totalling $1,805,945.42. Following the completion of the sale, the chairman now directly owns 2,021 shares of the company's stock, valued at $128,818.54. Learn More on Stanley T. Crooke's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $181,100.00. During the last year, insiders at the sold shares 18 times. They sold a total of 141,263 shares worth more than $4,915,939.91. The most recent insider tranaction occured on April, 16th when EVP Brian Birchler sold 680 shares worth more than $19,291.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 4/16/2025.

Stanley T. Crooke Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/26/2021	Sell	28,333	$63.74	$1,805,945.42	2,021
1/21/2021	Sell	35,000	$61.20	$2,142,000.00	30,354
12/17/2020	Sell	1,407	$50.50	$71,053.50	2,021
12/15/2020	Sell	39,000	$49.78	$1,941,420.00	2,021
12/7/2020	Sell	11,000	$51.67	$568,370.00	2,021
11/25/2020	Sell	12,990	$50.05	$650,149.50	15,011
11/23/2020	Sell	11,600	$50.11	$581,276.00	13,621
9/21/2020	Sell	2,000	$50.18	$100,360.00	2,021
6/24/2020	Sell	5,000	$58.80	$294,000.00	11,935
6/19/2020	Sell	10,000	$58.33	$583,300.00	26,935
6/17/2020	Sell	15,000	$57.90	$868,500.00	26,935
3/25/2020	Sell	15,000	$47.00	$705,000.00	41,935
3/19/2020	Sell	15,000	$45.17	$677,550.00	61,545
8/21/2019	Sell	22,000	$71.52	$1,573,440.00	79,634
7/18/2019	Sell	10,000	$70.25	$702,500.00	79,634
4/16/2019	Sell	32,000	$84.84	$2,714,880.00	79,634
2/26/2019	Sell	77,000	$60.77	$4,679,290.00	109,634
2/13/2019	Sell	46,904	$60.09	$2,818,461.36	109,634
4/17/2018	Sell	13,962	$44.40	$619,912.80	56,714
1/29/2018	Sell	11,000	$54.12	$595,320.00
1/15/2018	Sell	16,549	$51.76	$856,576.24	67,626
1/8/2018	Sell	11,000	$52.01	$572,110.00	48,014
1/3/2018	Sell	22,000	$50.01	$1,100,220.00	58,014
10/13/2017	Sell	16,500	$59.46	$981,090.00
10/4/2017	Sell	27,500	$52.89	$1,454,475.00
10/2/2017	Sell	15,000	$52.00	$780,000.00	43,014
7/20/2017	Sell	11,000	$55.35	$608,850.00	48,014
7/17/2017	Sell	16,500	$52.45	$865,425.00	53,014
7/3/2017	Sell	16,500	$52.10	$859,650.00	51,476
4/25/2017	Sell	16,500	$47.81	$788,865.00	53,014
4/19/2017	Sell	5,500	$43.25	$237,875.00	43,014
4/13/2017	Sell	22,000	$40.69	$895,180.00	48,014
1/17/2017	Sell	15,382	$46.29	$712,032.78	30,576
1/10/2017	Sell	13,200	$49.25	$650,100.00	37,029
1/4/2017	Sell	18,700	$48.89	$914,243.00	30,029
10/5/2016	Sell	11,000	$36.61	$402,710.00	35,029
9/27/2016	Sell	22,000	$36.02	$792,440.00	45,029
9/21/2016	Sell	22,000	$35.50	$781,000.00	45,029
4/6/2016	Sell	11,000	$46.13	$507,430.00	30,029
3/31/2016	Sell	11,000	$40.74	$448,140.00	30,029
1/19/2016	Sell	13,401	$41.46	$555,605.46	25,029
1/5/2016	Sell	5,500	$62.10	$341,550.00	14,642
1/4/2016	Sell	11,000	$61.05	$671,550.00	14,642
10/23/2015	Sell	44,000	$43.85	$1,929,400.00	14,642
7/6/2015	Sell	5,000	$57.01	$285,050.00
7/1/2015	Sell	6,175	$57.56	$355,433.00
4/7/2015	Sell	22,377	$63.07	$1,411,317.39
1/27/2015	Sell	11,000	$72.93	$802,230.00
1/16/2015	Sell	9,054	$67.96	$615,309.84
1/9/2015	Sell	11,000	$73.57	$809,270.00
1/7/2015	Sell	22,000	$67.04	$1,474,880.00
10/23/2014	Sell	14,600	$42.22	$616,412.00
10/3/2014	Sell	36,000	$38.52	$1,386,720.00
10/1/2014	Sell	20,000	$37.91	$758,200.00
8/13/2014	Sell	15,500	$35.45	$549,475.00
8/1/2014	Sell	16,000	$30.53	$488,480.00
7/1/2014	Sell	17,500	$35.57	$622,475.00
6/19/2014	Sell	11,000	$35.10	$386,100.00
6/10/2014	Sell	11,000	$33.46	$368,060.00
7/23/2013	Sell	11,500	$30.00	$345,000.00
7/22/2013	Sell	62,200	$30.50	$1,897,100.00
7/17/2013	Sell	49,300	$33.12	$1,632,816.00
7/12/2013	Sell	90,000	$31.75	$2,857,500.00
7/9/2013	Sell	109,172	$26.69	$2,913,800.68
7/1/2013	Sell	50,683	$27.65	$1,401,384.95
6/26/2013	Sell	90,000	$26.73	$2,405,700.00
1/16/2013	Sell	1,460	$14.00	$20,440.00

See Full Table

Stanley T. Crooke Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $29.70

$28.87

$29.90

50 Day Range

MA: $30.68

$25.51

$34.39

2 Week Range

Now: $29.70

$23.95

$52.34

Volume

1,015,576 shs

Average Volume

1,527,660 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29